Vrishab Sathish Kumar

MD/PhD Student | Case Western Reserve University

Computational Immuno-Oncology

Investigating brain tumors @TyMillerLab

Views are my own.

[Ty Miller Lab @TyMillerLab]

Why has immunotherapy been so hard in glioblastoma?

A major reason is the immune microenvironment.

In this open-access review, we summarize how single-cell genomics is changing our understanding of glioma immune biology — and why we need to think beyond cell types.
https://t.co/e5Tk3jJek1

[gelareh-zadeh @gelarehzadeh]

a special edition summarizing the discoveries & advances made through #singlecell #analysis #braintumors
@EditorNeuro @YosefEllenbogen @TiroshLab @MarioSuva perfect #team to bring the field this body of work

[Editor - Neuro-Oncology Advances @EditorNeuro]

Our new supplement on #SingleCell Technologies is now available!

Click here for open access articles: https://t.co/SyCpLEUMP6

[The Sontag Foundation @sontagfdn]

We are pleased to recognize Dr. Tyler Miller as a 2025 Distinguished Scientist Award Recipient.

"We believe this project will result in meaningful contributions to the field of brain cancer research.” -Hilary Keeley.

Read more: https://t.co/1F6cHgtuqr
@TyMillerLab

[Rich Law @drrichjlaw]

This is why everyone working on the same targets in biotech/pharma (VCs) hurts everyone. 220 clinical trials of TIGIT inhibs cost ~$3.5Bn & involved 15,000 patients. None worked. Herding amplifies loss in an industry that has a 95% failure rate. https://t.co/3ZA9Zmy35E

[Justin Lathia, PhD 🧠🕺🏽 @JustinLathia]

Great #CLE @CCLRI @caseccc end of year joint lab meeting! What a great year, looking forward to 2026! 🎄🎅

[Ty Miller Lab @TyMillerLab]

I am so excited for, and proud of, @vrishab_x for receiving an offer letter from @cwrumstp today! The whole lab was celebrating for him, & immediately got a cake 🥳🍾
He has worked so hard for this experience into an MSTP and is incredibly deserving. He will be a rockstar wherever he lands (hopefully @CWRUSOM) 😉

[Vrishab Sathish Kumar @vrishab_x]

@JustinLathia Congratulations!

[Cell @CellCellPress]

Now online! Macrophage-targeted immunocytokine leverages myeloid, T, and NK cell synergy for cancer immunotherapy https://t.co/1JmfQeH9Y7

[Ty Miller Lab @TyMillerLab]

We celebrated our lab, and all the places and cultures that influence us, with an international potluck dinner over the weekend! So grateful for this group. Not only are they dedicated and talented scientists, but they also make incredible food and make the lab a fun place to be everyday!

Thanks to @Shawn_T_Ho for organizing and to @Joycelab for the inspiration!

[Vrishab Sathish Kumar @vrishab_x]

@tangming2005 Entirely agree!

[Ming "Tommy" Tang @tangming2005]

1/ Many bioinformatics students don’t know much about NGS pre-processing. But trust me, understanding the raw data is essential. Here’s why.

[Ming "Tommy" Tang @tangming2005]

Reproducible single-cell annotation of programs underlying T cell subsets, activation states and functions https://t.co/b65uccm4XU

[Jorge Bravo Abad @bravo_abad]

One of the quiet privileges of academia: you spend your days surrounded by some of the brightest people on the planet — all trying to understand something deeply. Not to sell it, not to exploit it, just to understand. That changes you.

[Nature Methods @naturemethods]

Nimbus predicts the likelihood of marker positivity from multiplexed image data in single cells.

https://t.co/hkJtpQRSbQ

[The Nobel Prize @NobelPrize]

BREAKING NEWS
The 2025 #NobelPrize in Physiology or Medicine has been awarded to Mary E. Brunkow, Fred Ramsdell and Shimon Sakaguchi “for their discoveries concerning peripheral immune tolerance.”

[Dr. Jocelynn Pearl @JocelynnPearl]

Fine, I’ll say it. ArsenalBio really raised $325M for their company and then laid off 50% of the people who helped them get there… sending them out into one of the worst job markets for the field in recent history. Justifying it by saying they are shifting away from early stage research. As if you can’t retrain or give intelligent people a chance to pivot as well. And if I had to bet, a few people at the top got promotions. Shame on this industry for not standing by its people. There’s no loyalty. Maybe the people making these decisions can sleep at night by telling themselves “everyone is doing it” because unfortunately, ArsenalBio isn’t alone in this type of move. It’s just that there’s something so cold about the layoff announcement happening less than 2 weeks after that mega fundraising…

Give your people a chance. They fought for you and your science during one of the most competitive markets out there.
Ask your clinical, quality, tech, product, CMC etc to see if any early stage researchers could fit into their teams. Don’t just send them (and their families) out to fight for a new role in this market.

[Jennifer Guerriero, PhD @JennGuerriero]

PSA: Stop calling macrophages in tissue M1 or M2. These are not states that exist in biology. The only use of M1 is a macrophage cultured ex vivo with LPS and IFNg; and for M2: IL-4/13/10. Macrophages in tissues are highly complex and diverse and do not resemble either of the aforementioned M1/M2 states. M1/M2 language causes confusion and sets the field back. Refer to your macrophages by the molecules they express and the cytokines they make.

[Alex Landry @ap_landry]

Our new special edition on brain tumor immunotherapy is out today in @EditorNeuro, led by world-experts @GavinPDunn @MichaelLimMD. Thanks to authors, peer-reviewers, and editors for the invaluable contributions @gelarehzadeh @FarshadNassiri @OUPAcademic https://t.co/tqxQRoJIJ4

[Case Comp Cancer Ctr @caseccc]

It’s a great day for a bike ride! And an even better day to support @caseccc riders at @bikeVeloSano as they ride to support cancer research. Donate Today! https://t.co/NvpbZoFu4W